<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Surveillance for metastatic disease after definitive treatment for renal cell carcinoma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Surveillance for metastatic disease after definitive treatment for renal cell carcinoma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Surveillance for metastatic disease after definitive treatment for renal cell carcinoma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brian Shuch, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan J Pantuck, MD, MS, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Izak Faiena, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 03, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>For patients with renal cell carcinoma (RCC), surgery may be curative when patients present with localized disease. However, many patients who are initially resected eventually relapse, and the prognosis in these cases is often poor. Thus, optimal management requires careful surveillance for recurrent disease in those who have undergone a potentially curative resection.</p><p>The timing and patterns of recurrent and/or metastatic disease and specific recommendations for surveillance following the initial treatment of localized RCC will be reviewed here. An overview of the treatment of RCC is presented separately. (See  <a class="medical medical_review" href="/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>The advantages of an aggressive surveillance program must be balanced against the financial costs, radiation exposure, and psychological distress that repeated testing can cause the patient. The rationale for surveillance is based upon several observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of recurrence while the metastatic burden is limited may increase the likelihood of a favorable response to systemic treatment. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Advanced renal cell carcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical resection of a single or limited number of metastases or an isolated locoregional recurrence can result in long-term survival. (See  <a class="medical medical_review" href="/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma"</a> and <a class="local">'Locoregional recurrence'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early diagnosis of metastasis may minimize complications even if it does not affect survival (eg, prevention of pathologic fractures due to bone metastases).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asymptomatic recurrence detected by surveillance demonstrate improved survival compared with those with symptomatic recurrence [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to concerns about the development of metastatic disease, approximately 3 percent of patients with RCC will develop a metachronous de novo<em> </em>primary renal tumor [<a href="#rid2">2</a>].</p><p></p><p>The important factors in optimizing a surveillance protocol include the time after treatment when metastasis is most likely, the common sites of involvement, and the diagnostic approaches that are most effective in identifying recurrences.</p><p class="headingAnchor" id="H3"><span class="h1">TIME TO RECURRENCE</span></p><p class="headingAnchor" id="H2614791"><span class="h2">Duration of surveillance</span><span class="headingEndMark"> — </span>The greatest risk of recurrence following resection of RCC is in the first two to three years. As a result, the primary surveillance efforts focus on this period. From years 3 to 5, close follow-up with imaging can become less frequent.</p><p>The optimal time to discontinue surveillance is unclear, as there are patients who have local or distant recurrence greater than ten years after treatment [<a href="#rid3">3</a>]. As an example, a series of 1088 patients who recurred after kidney cancer surgery were assessed by current guidelines. There were significant numbers of recurrences missed by stopping surveillance after five years. Extending surveillance to 15 years would capture 95 percent of recurrences; however, it would be significantly more costly, with unproven benefit [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H2614797"><span class="h2">Late recurrences</span><span class="headingEndMark"> — </span>The features of patients with late recurrences were analyzed in a series of 1454 patients who were disease-free a minimum of five years after nephrectomy for localized RCC. With a median postoperative follow-up of 14 years, among those with recurrent disease, 63 patients (4 percent) had late relapse past five years. The estimated recurrence-free survival rates for a renal recurrence at 10 and 15 years after surgery were 97 and 95 percent, respectively. The distant metastasis-free survival rates at 10 and 15 years were 93 and 86 percent, respectively [<a href="#rid5">5</a>].</p><p>On multivariate analysis, risk factors associated with late distant metastasis included:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumor size (1 centimeter increase; hazard ratio [HR] 1.07, 95% CI 1.01-1.14)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumor stage (versus T1a)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>pT1b (HR 2.81, 95% CI 1.61-4.91)</p><p class="bulletIndent2"><span class="glyph">•</span>pT2a (HR 4.45, 95% CI 2.34-8.47)</p><p class="bulletIndent2"><span class="glyph">•</span>pT2b (HR 3.38, 95% CI 1.39-8.23)</p><p class="bulletIndent2"><span class="glyph">•</span>pT3a to pT3b, pT3c, pT4 (HR 5.09, 95% CI 2.68-9.67)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Histology (versus chromophobe/papillary)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clear cell, collecting duct, or histology not otherwise specified (HR 3.76, 95% CI 2.12-6.66)</p><p></p><p>In one cohort from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) of 1210 patients with metastatic RCC, late recurrence (&gt;5 years) occurred in 313 patients (26 percent). Predictors of late recurrence included younger age, absence of sarcomatoid features, clear cell histology, and lower Fuhrman grade [<a href="#rid6">6</a>].</p><p>Most surveillance protocols now recommend that a follow-up plan of duration greater than five years be individualized at the discretion of the treating clinician.</p><p class="headingAnchor" id="H4"><span class="h1">SITES OF METASTASIS</span><span class="headingEndMark"> — </span>The most common sites of metastatic disease from RCC are the lungs, bones, liver, renal fossa, and brain, although recurrences may occur elsewhere. Specific imaging studies of each region are necessary to detect recurrence. </p><p>While other malignancies utilize whole body imaging with fludeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), the utility of this modality is limited for RCC, due in part to limited FDG activity in many renal tumors as well as the physiological excretion of FDG into the urine. While the latter in particular limits the role of FDG PET/CT in the initial diagnosis and staging of RCC, the role of FDG PET/CT has also been met with mixed results in the restaging of RCC after nephrectomy [<a href="#rid7">7</a>], and FDG PET/CT is currently not recommended for this purpose based upon current guidelines.</p><p class="headingAnchor" id="H5"><span class="h2">Lung metastases</span><span class="headingEndMark"> — </span>Lung metastases have been reported in 29 to 54 percent of patients with recurrent RCC and are the most common site of metastatic disease [<a href="#rid8">8-10</a>]. Office assessment of any pulmonary complaints, such as cough or shortness of breath, should occur with each office visit. </p><p>All surveillance protocols incorporate periodic imaging of the lungs. Whether CT or plain chest radiograph is optimal remains uncertain, although CT is now being used more routinely. It is not clear that the increased sensitivity of chest CT offers additional benefit compared with plain chest radiograph. Many risk-stratified protocols utilize chest CT for high-risk populations but do mention alternating usage with chest radiography [<a href="#rid11">11,12</a>]. (See <a class="local">'Surveillance protocols'</a> below.)</p><p class="headingAnchor" id="H6"><span class="h2">Bone metastases</span><span class="headingEndMark"> — </span>Office visits should assess if there is any bone or joint pain or unexplained fractures. Bone metastases have been observed in 16 to 31 percent of patients with recurrent RCC, and 67 to 91 percent of those with bone metastasis present with localized pain due to their lytic nature [<a href="#rid8">8-10,13-15</a>]. Early identification and treatment of bone metastases can prevent pathologic fractures, minimize pain, and maintain function [<a href="#rid16">16,17</a>]. (See  <a class="medical medical_review" href="/d/html/2805.html" rel="external">"Radiation therapy for the management of painful bone metastases"</a> and  <a class="medical medical_review" href="/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a> and  <a class="medical medical_review" href="/d/html/14249.html" rel="external">"Rehabilitative and integrative therapies for pain in patients with cancer"</a>.)</p><p>Most surveillance strategies to detect bone metastases rely upon the history, physical examination, and measurement of serum alkaline phosphatase. Routine imaging with plain films or bone scan is not recommended, and these tests are reserved to confirm a suspicion of metastasis and to evaluate suspicious findings observed on chest and abdominal scans. (See <a class="local">'Surveillance protocols'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone scan</strong> – The use of a radionuclide bone scan beyond that of history and physical examination is generally restricted to symptomatic patients. This was illustrated in a series of 1357 patients with RCC [<a href="#rid18">18</a>]. Among the 167 cases with bone metastases, 96 percent were symptomatic, with an Eastern Cooperative Oncology Group (ECOG) performance score of 1 or greater  (<a class="graphic graphic_table graphicRef72901" href="/d/graphic/72901.html" rel="external">table 1</a>). Among all patients who were asymptomatic (ie, a performance score of 0), only 1.4 percent had bone metastases. In addition, bone scans may be relatively insensitive at detecting the largely lytic metastatic lesions occurring in RCC.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alkaline phosphatase</strong> – Monitoring the serum alkaline phosphatase is simple and inexpensive, but elevated values are seen in only 40 to 55 percent of patients with documented bone metastasis; in addition, its specificity is poor [<a href="#rid14">14,18</a>]. Elevations in serum alkaline phosphatase may also be due to liver metastases or a paraneoplastic syndrome. (See  <a class="medical medical_review" href="/d/html/3612.html" rel="external">"Enzymatic measures of hepatic cholestasis (alkaline phosphatase, 5'-nucleotidase, gamma-glutamyl transpeptidase)"</a> and  <a class="medical medical_review" href="/d/html/2983.html" rel="external">"Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Hepatic dysfunction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PET/CT</strong> – Detection of bone lesions using cross-sectional imaging and bone scans can be challenging. Cross-sectional imaging modalities do not image the axial skeleton, and there are inherent limitations of bone scans due to the osteolytic nature of bone metastases. FDG PET/CT imaging may have a role in detecting bone metastases, with some observational series demonstrating improved sensitivity/accuracy at detecting bone metastases compared with conventional bone scan [<a href="#rid19">19</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Liver metastases</span><span class="headingEndMark"> — </span>Metastases to the liver have been reported in between 8 and 30 percent of patients with recurrent RCC [<a href="#rid8">8-10,13,18</a>]. In approximately 90 percent of cases, such metastases are detected because of symptoms or abnormal laboratory values [<a href="#rid9">9,13</a>]. Consequently, all surveillance regimens utilize periodic history, physical examination, and liver function tests to assess for symptoms, hepatomegaly, and laboratory abnormalities. Abdominal CT or magnetic resonance imaging (MRI) is the best tool to detect liver metastases, which may be present even in the absence of symptoms or abnormal liver function tests [<a href="#rid9">9,13</a>].</p><p>Early detection of liver metastases allows carefully selected patients to undergo local therapies such as microwave/radiofrequency ablation or metastasectomy, although the evidence supporting the clinical benefit of such an approach is anecdotal [<a href="#rid20">20,21</a>]. (See <a class="local">'Surveillance protocols'</a> below and  <a class="medical medical_review" href="/d/html/2963.html" rel="external">"Role of surgery in patients with metastatic renal cell carcinoma", section on 'Liver metastases'</a>.)</p><p class="headingAnchor" id="H11"><span class="h2">Locoregional recurrence</span><span class="headingEndMark"> — </span>Locoregional recurrence can result from metastatic disease to the ipsilateral adrenal gland, regional lymph nodes, perirenal fat or Gerota's fascia, invasion into the psoas muscle, or due to tumor spillage. Local recurrence is more common in patients with locally advanced tumors and those with sarcomatoid histology [<a href="#rid9">9</a>].</p><p>Although the rate of isolated local recurrence following radical nephrectomy varies with patient selection, such relapses are uncommon. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of over 1700 patients from the Mayo Clinic who underwent radical nephrectomy for localized (T1-T3N0M0) RCC  (<a class="graphic graphic_table graphicRef110735" href="/d/graphic/110735.html" rel="external">table 2</a>), isolated recurrence in the renal fossa was identified in less than 2 percent [<a href="#rid22">22</a>]. Of these 30 patients with isolated local recurrence, 60 percent were symptomatic and 40 percent were found on routine follow-up evaluation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a subgroup analysis of a randomized trial (ASSURE), among 300 patients with intermediate-/high-risk nonmetastatic disease with local recurrences, 22 percent (66 patients) experienced recurrences in the kidney/renal fossa. However, in the overall study population of 1943 patients, this represented an isolated local recurrence rate of only 3 percent [<a href="#rid23">23</a>]. Further details on the ASSURE trial are discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy for locoregional disease'</a>.)</p><p></p><p>Early diagnosis of patients with isolated local recurrence is important because surgical resection of such relapses may improve outcome by preventing progression to disseminated disease [<a href="#rid22">22,24,25</a>]. Retrospective series have evaluated the outcome following such resection, although this presumably represents a highly selected population. As an example, in 102 patients who underwent resection of an isolated retroperitoneal recurrence at MD Anderson Cancer Center, metastatic progression was observed in 59 percent with a median follow-up of 32 months [<a href="#rid25">25</a>]. Approximately 30 percent of patients remained recurrence-free at 10 years of follow-up. The median cancer-specific survival with resection of a local recurrence was more than five years.</p><p>For soft tissue recurrences away from the great vessels, percutaneous ablation is possible. However, as the bowel often migrates into the renal fossa, hydrodissection of the bowel is necessary to avoid inadvertent damage to adjacent organs.</p><p>Limited data are available for resection of local recurrence after partial nephrectomy; however, these tumors are often smaller and lower stage, and thus are likely to have similar or improved outcomes with surgery.</p><p>Although the incidence of isolated local recurrence is low, abdominal CT is recommended to simultaneously evaluate for liver metastasis and local recurrence. While abdominal ultrasound is included in some surveillance algorithms, it may be insufficient for identification of locoregional recurrences. (See <a class="local">'Surveillance protocols'</a> below.)</p><p class="headingAnchor" id="H4010992650"><span class="h2">Renal recurrences</span><span class="headingEndMark"> — </span>In the presence of advanced disease, a new renal lesion may represent either an independent lesion or a de novo recurrence. Without distant disease, the majority of lesions are independent tumors with the exception of tumors after partial nephrectomy, which recur in the surgical bed. Metachronous renal tumors may be more common than previously thought in some populations. While the 10- and 20-year cumulative incidence is relatively low (1.5 and 3.1 percent, respectively), specific factors such as age &lt;40, male gender, being from a Black population, and papillary histology are significant risk factors [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Brain metastases</span><span class="headingEndMark"> — </span>Brain metastases occur in 2 to 10 percent of patients with recurrent RCC [<a href="#rid8">8-10,13</a>] and are symptomatic in ≥80 percent of cases [<a href="#rid15">15,22,27,28</a>]. Affected patients can present with headaches, altered behavior, seizures, or focal neurologic symptoms. (See  <a class="medical medical_review" href="/d/html/5217.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of brain metastases", section on 'Clinical manifestations'</a>.)</p><p>Brain metastases are accompanied by other sites of metastatic disease in most cases [<a href="#rid27">27-29</a>]. As an example, in a single-institution series of 138 patients with brain metastases, 95 percent had extracranial sites of metastasis when brain metastases were diagnosed [<a href="#rid29">29</a>]. In a separate series of 158 patients, 91 percent had additional sites of disease [<a href="#rid30">30</a>]. Despite historically poor outcome, carefully selected patients with good performance statuses and brain metastases can demonstrate long-term survival with aggressive therapy [<a href="#rid29">29</a>]. With improvements in local and systemic therapy, these patients have experienced significantly improved outcomes [<a href="#rid30">30</a>].</p><p>Screening asymptomatic patients in the absence of other documented distant disease is not recommended given the low incidence of brain metastasis, high incidence of symptomatic presentation, and frequent association with extracranial sites of metastasis [<a href="#rid8">8-10,13</a>]. However, if recurrence at other sites is detected, brain imaging may be considered as it could identify small asymptomatic lesions that could be amenable to radiation. MRI and CT are both useful for evaluation of symptomatic patients or at the time of extracranial recurrence. Currently, there is no specific preference per major guidelines for MRI versus CT. Although MRI has greater sensitivity for small asymptomatic brain lesions, in the setting of a symptomatic patient that may require an emergent evaluation and treatment, CT can be obtained more expeditiously in most centers.</p><p>For individuals being considered for immunotherapy or antiangiogenic therapy, brain imaging is useful to document the absence of disease because of the risk of treatment-associated toxicity or hemorrhage. </p><p>The approach to treating brain metastases from RCC is discussed separately. (See  <a class="medical medical_review" href="/d/html/5212.html" rel="external">"Overview of the treatment of brain metastases"</a>.)</p><p class="headingAnchor" id="H2615463"><span class="h2">Impact of histology</span><span class="headingEndMark"> — </span>The patterns of metastatic spread have been analyzed based upon the histologic subtype of RCC [<a href="#rid31">31</a>]. In this analysis, clear cell tumors preferentially spread to the lungs, while chromophobe tumors more frequently metastasized to the liver. Based on differential sites of metastasis and time to metastasis, histology-specific protocols have been recommended with differential chest and abdominal imaging surveillance intervals [<a href="#rid32">32</a>]. While further refining risk stratification, these protocols have not been widely adopted. (See <a class="local">'Surveillance protocols'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h1">SURVEILLANCE PROTOCOLS</span><span class="headingEndMark"> — </span>The two most widely used surveillance protocols following definitive treatment for RCC are those from the American Urologic Association (AUA) and the National Comprehensive Cancer Network (NCCN). Both of these surveillance protocols utilize a risk-stratified approach, whereas first-generation models did not stratify by stage or tumor grade [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H10800225"><span class="h2">AUA guidelines</span><span class="headingEndMark"> — </span>The AUA recommends specific guidelines for surveillance after surgical management of RCC [<a href="#rid34">34</a>]. These guidelines were developed based on a systematic review of the literature:</p><p class="headingAnchor" id="H10800234"><span class="h3">Stage I or T1N0/X (partial or radical nephrectomy)</span></p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination at months 6, 12, 24, and 36 and further follow-up at the discretion of the treating clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum blood urea nitrogen (BUN) or creatinine and urine analysis are recommended and other tests as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal imaging:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After partial nephrectomy – Baseline abdominal computed tomography (CT)/magnetic resonance imaging (MRI) at month 6 and then abdominal CT/MRI/or ultrasound (US) at 12, 24, and 36 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>After radical nephrectomy – Baseline abdominal CT, MRI at month 6 then imaging as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest imaging – Chest radiograph or CT annually for three years, then as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system (CNS) imaging, pelvic imaging, and bone imaging as clinically indicated.</p><p></p><p class="headingAnchor" id="H10800269"><span class="h3">PT2-4N0/X or pTanyN1</span></p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination every six months until five years and further follow-up at the discretion of the treating clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BUN or creatinine and urinalysis; other tests as clinically indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal imaging – CT/MRI recommended at month 6, after which CT/MRI/US use acceptable for abdominal imaging every six months until five years, with further follow-up at the discretion of the treating clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest imaging – Chest CT initially at month 6 followed by chest radiograph or CT every six months until five years, and further follow-up at the discretion of the treating clinician.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CNS imaging, pelvic imaging, and bone imaging as clinically indicated.</p><p></p><p class="headingAnchor" id="H2615275"><span class="h2">NCCN guidelines</span><span class="headingEndMark"> — </span>The National Comprehensive Cancer Network (NCCN) guidelines include the following risk-stratified recommendations [<a href="#rid11">11</a>]:</p><p class="headingAnchor" id="H2615289"><span class="h3">Stage I</span></p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination annually and basic laboratory studies annually as indicated. Additional imaging of brain, bone, or pelvis based upon clinical indications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest imaging (either CT or plain radiograph) annually for five years or longer based on clinical judgment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal imaging with CT, MRI (preferred), or US within the first year after surgery. This should be repeated at years 2 and 3 or longer based on clinical judgment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More intensive follow-up schedule can be offered to patients with high-risk features (eg, sarcomatoid, high grade, or positive margins).</p><p></p><p class="headingAnchor" id="H2615296"><span class="h3">Stage II/III</span></p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination every three to six months for the first three years and then annually through year 5. Additional imaging of brain, bone, or pelvis based upon symptoms and clinical indications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive laboratory studies every six months for the first two years and then annually through year 5. Longer evaluation may be offered based on clinical judgment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chest CT every three to six months through year 3 and then annually through year 5. Longer evaluation may be offered based on clinical judgment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abdominal imaging with CT, MRI (preferred), or US at three- to six-month intervals for first three years and then annually through year 5. Longer evaluation may be offered based on clinical judgment.</p><p></p><p class="headingAnchor" id="H2133430818"><span class="h2">Nomograms</span><span class="headingEndMark"> — </span>A wide variety of factors are known to be independent prognostic indicators of tumor progression and influence cancer-specific survival. Prognostic models incorporate factors related to tumor anatomy, histology, and clinical presentation. Many prognostic models are available that can fairly accurately stratify patients more likely to recur [<a href="#rid34">34-39</a>]. Some of these, such as the University of California, Los Angeles (UCLA) Integrated Staging System [<a href="#rid35">35,40</a>] or the Mayo Clinic Leibovich prognostic model [<a href="#rid36">36,41</a>], have been used for clinical trial selection. However, many of these predictive models perform poorly in high-risk cohorts, as illustrated from one study using data from the ASSURE trial [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma", section on 'Clinical factors'</a>.)</p><p class="headingAnchor" id="H23"><span class="h2">Biomarkers and the future of surveillance</span><span class="headingEndMark"> — </span>Over the past 10 years, multiple biomarkers have been linked to increased risk of recurrence after nephrectomy. As these are validated, such biomarkers may enable refinements in surveillance protocols following definitive treatment of RCC.</p><p>Both UCLA and Mayo groups have developed predictive models that incorporate panels of biomarkers with clinicopathologic information [<a href="#rid35">35,36</a>]. The addition of these biomarkers appears to improve the predictive capability of these models. Neither model has been externally or prospectively validated, but this concept probably represents the future of prognostication.</p><p>Challenges to the adoption of these biomarker-based systems include the variability of tissue preparation and storage, and in interpretation of immunohistochemical scoring [<a href="#rid37">37</a>]. For these reasons, a cytogenetic approach may be more easily adopted as many centers have facilities capable of performing this technique. Cytogenetic evaluation of renal tumors has been routinely performed at UCLA, and assessment of chromosomal alterations can aid in prognostication [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2961.html" rel="external">"Prognostic factors in patients with renal cell carcinoma", section on 'Molecular markers'</a>.)</p><p>With the expansion of genomic characterization, there is some hope that next-generation sequencing could assist with prognostication. Specific mutations in chromatin remodeling genes such as <em>BAP1</em> may lead to a worse prognosis [<a href="#rid39">39,43</a>]. Challenges exist in using genomic sequencing to determine mutational status due to significant intra-tumor heterogeneity. A biopsy of a single site may not adequately assess a specific gene alteration, as over half of mutations in driver alterations are often not shared throughout the tumor.</p><p class="headingAnchor" id="H263461748"><span class="h1">SURVEILLANCE AFTER THERMOABLATION</span><span class="headingEndMark"> — </span>Thermoablation is an alternative to partial nephrectomy in selected patients with clinical T1 RCC [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/2970.html" rel="external">"Diagnostic approach, differential diagnosis, and management of a small renal mass"</a> and  <a class="medical medical_review" href="/d/html/3001.html" rel="external">"Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma"</a>.)</p><p>Both radiofrequency ablation and cryoablation can be performed through an open, laparoscopic, or percutaneous approach, and it appears that both procedures have similar oncologic outcomes. The American Urological Association (AUA) guidelines suggest that for those patients who are candidates for ablation, a percutaneous approach is preferred, when feasible, to minimize the morbidity of other approaches [<a href="#rid12">12</a>]. Compared with partial nephrectomy, there is a 5- to 20-fold increased risk for local recurrence, while the risk for developing distant metastases appears to be similar [<a href="#rid44">44,45</a>]. There may be a role for risk stratification, as increased surveillance may be required for larger lesions and less surveillance may be required for lesions of indolent potential, such as a fat-poor angiomyolipoma.</p><p>With the higher rate of local recurrence, it is crucial to monitor the ablated kidney with either contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI). National Comprehensive Cancer Network (NCCN) guidelines recommend such imaging within three to six months following ablation, followed by annual imaging for up to five years or longer as clinically indicated. However, given the high risk of local recurrence, it is prudent to offer postablation imaging on a more frequent schedule. Our approach is to perform CT or MRI imaging at three to six, 12, 18, and 24 months after ablation, and yearly thereafter. The proposed abdominal surveillance scheme is similar to the one for the intermediate- and high-risk groups of patients treated with nephrectomy. Chest imaging can be performed similar to that for other patients with similar disease characteristics managed with surgical resection. Recurrent tumors can often be successfully retreated with ablation. (See  <a class="medical medical_review" href="/d/html/3001.html" rel="external">"Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma", section on 'Surveillance after ablation'</a>.)</p><p>A repeat renal mass biopsy should be considered with new renal enhancement after ablative therapy but may be performed at the time of repeat ablation [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H3420528"><span class="h1">SURVEILLANCE AFTER ADJUVANT THERAPY</span><span class="headingEndMark"> — </span>Some patients with renal cell carcinoma (RCC) who are treated with surgical resection and are at increased risk for recurrence may receive adjuvant systemic therapy (such as <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>). Surveillance performed during and following adjuvant therapy should follow the stage and risk categorization of the initial surgical tumor staging. </p><p>The approach to adjuvant therapy in resected RCC (including patient selection and available agents) is discussed separately. (See  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy for locoregional disease'</a> and  <a class="medical medical_review" href="/d/html/15719.html" rel="external">"Overview of the treatment of renal cell carcinoma", section on 'Adjuvant therapy after metastasectomy'</a>.) </p><p class="headingAnchor" id="H3948254681"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119821.html" rel="external">"Society guideline links: Cancer of the kidney and ureters"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale </strong>– The rationale for surveillance following resection is based upon indirect evidence from patients who are treated for metastatic disease. There are no randomized trials demonstrating increased survival from specific surveillance practices following definitive therapy. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance protocols</strong> – Following complete resection of renal cell carcinoma (RCC), patients should be monitored for evidence of local recurrence, distant metastasis, or a second primary RCC. Contemporary recommendations for surveillance incorporate information from the tumor, node, metastasis (TNM) staging system along with other key prognostic factors. (See <a class="local">'Surveillance protocols'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surveillance protocols focus on the sites most frequently involved with metastases, including the lungs, bones, liver, and renal fossa, and match testing with the period of greatest risk of recurrence. These surveillance protocols must be adjusted for the needs of the individual patient based upon clinical judgment and experience. (See <a class="local">'Sites of metastasis'</a> above and <a class="local">'Time to recurrence'</a> above and <a class="local">'Surveillance protocols'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Guidelines from the American Urological Association (AUA) and the National Comprehensive Cancer Network (NCCN) are similarly efficient in detecting both locoregional and distant metastases and provide a useful tool for patient management. Both of these guidelines incorporate an estimate of the risk of recurrence based upon extent of disease. (See <a class="local">'AUA guidelines'</a> above and <a class="local">'NCCN guidelines'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance after thermoablation</strong> – Patients whose tumor has been managed with thermoablation (eg, cryotherapy, radiofrequency ablation) should have surveillance abdominal imaging performed on a schedule similar to that for patients with intermediate- or high-risk disease treated with nephrectomy, because of the increased risk of local recurrence. (See <a class="local">'Surveillance after thermoablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surveillance after adjuvant therapy</strong> – For patients treated with resected RCC followed by adjuvant systemic therapy, surveillance performed during and following adjuvant therapy should follow the stage and risk categorization of the initial surgical tumor staging. (See <a class="local">'Surveillance after adjuvant therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H1729027021"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Tobias Klatte, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Antonelli A, Cozzoli A, Zani D, et al. The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol. BJU Int 2007; 99:296.</a></li><li><a class="nounderline abstract_t">Klatte T, Patard JJ, Wunderlich H, et al. Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 2007; 177:2081.</a></li><li><a class="nounderline abstract_t">Miyao N, Naito S, Ozono S, et al. Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer. Urology 2011; 77:379.</a></li><li><a class="nounderline abstract_t">Stewart SB, Thompson RH, Psutka SP, et al. Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines. J Clin Oncol 2014; 32:4059.</a></li><li><a class="nounderline abstract_t">Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology 2011; 78:1101.</a></li><li><a class="nounderline abstract_t">Kroeger N, Choueiri TK, Lee JL, et al. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. Eur Urol 2014; 65:1086.</a></li><li><a class="nounderline abstract_t">Fuccio C, Ceci F, Castellucci P, et al. Restaging clear cell renal carcinoma with 18F-FDG PET/CT. Clin Nucl Med 2014; 39:e320.</a></li><li><a class="nounderline abstract_t">Ljungberg B, Alamdari FI, Rasmuson T, Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999; 84:405.</a></li><li><a class="nounderline abstract_t">Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998; 159:1163.</a></li><li><a class="nounderline abstract_t">Hafez KS, Novick AC, Campbell SC. Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma. J Urol 1997; 157:2067.</a></li><li class="breakAll">Kidney Cancer: NCCN Clinical Practice Guidelines in Oncology http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (Accessed on June 16, 2019).</li><li><a class="nounderline abstract_t">Campbell S, Uzzo RG, Allaf ME, et al. Renal Mass and Localized Renal Cancer: AUA Guideline. J Urol 2017; 198:520.</a></li><li><a class="nounderline abstract_t">Sandock DS, Seftel AD, Resnick MI. A new protocol for the followup of renal cell carcinoma based on pathological stage. J Urol 1995; 154:28.</a></li><li><a class="nounderline abstract_t">Seaman E, Goluboff ET, Ross S, Sawczuk IS. Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma. Urology 1996; 48:692.</a></li><li><a class="nounderline abstract_t">Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395.</a></li><li><a class="nounderline abstract_t">Baloch KG, Grimer RJ, Carter SR, Tillman RM. Radical surgery for the solitary bony metastasis from renal-cell carcinoma. J Bone Joint Surg Br 2000; 82:62.</a></li><li><a class="nounderline abstract_t">Kollender Y, Bickels J, Price WM, et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol 2000; 164:1505.</a></li><li><a class="nounderline abstract_t">Shvarts O, Lam JS, Kim HL, et al. Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans. J Urol 2004; 172:867.</a></li><li><a class="nounderline abstract_t">Alongi P, Picchio M, Zattoni F, et al. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT. Eur J Nucl Med Mol Imaging 2016; 43:464.</a></li><li><a class="nounderline abstract_t">Franklin JR, Figlin R, Rauch J, et al. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Semin Urol Oncol 1996; 14:230.</a></li><li><a class="nounderline abstract_t">Fujisaki S, Takayama T, Shimada K, et al. Hepatectomy for metastatic renal cell carcinoma. Hepatogastroenterology 1997; 44:817.</a></li><li><a class="nounderline abstract_t">Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol 2000; 164:322.</a></li><li><a class="nounderline abstract_t">Lee Z, Jegede OA, Haas NB, et al. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol 2020; 203:684.</a></li><li><a class="nounderline abstract_t">Sandhu SS, Symes A, A'Hern R, et al. Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma. BJU Int 2005; 95:522.</a></li><li><a class="nounderline abstract_t">Thomas AZ, Adibi M, Borregales LD, et al. Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. J Urol 2015; 194:316.</a></li><li><a class="nounderline abstract_t">Syed JS, Nguyen KA, Holford TR, et al. Risk factors for metachronous bilateral renal cell carcinoma: A surveillance, epidemiology, and end results analysis. Cancer 2019; 125:232.</a></li><li><a class="nounderline abstract_t">Mori Y, Kondziolka D, Flickinger JC, et al. Stereotactic radiosurgery for brain metastasis from renal cell carcinoma. Cancer 1998; 83:344.</a></li><li><a class="nounderline abstract_t">Hoshi S, Jokura H, Nakamura H, et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 2002; 9:618.</a></li><li><a class="nounderline abstract_t">Shuch B, La Rochelle JC, Klatte T, et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008; 113:1641.</a></li><li><a class="nounderline abstract_t">Suarez-Sarmiento A Jr, Nguyen KA, Syed JS, et al. Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study. Clin Genitourin Cancer 2019; 17:e1163.</a></li><li><a class="nounderline abstract_t">Hoffmann NE, Gillett MD, Cheville JC, et al. Differences in organ system of distant metastasis by renal cell carcinoma subtype. J Urol 2008; 179:474.</a></li><li><a class="nounderline abstract_t">Siddiqui SA, Frank I, Cheville JC, et al. Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol. BJU Int 2009; 104:778.</a></li><li><a class="nounderline abstract_t">Montie JE. Follow-up after partial or total nephrectomy for renal cell carcinoma. Urol Clin North Am 1994; 21:589.</a></li><li><a class="nounderline abstract_t">Donat SM, Diaz M, Bishoff JT, et al. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol 2013; 190:407.</a></li><li><a class="nounderline abstract_t">Klatte T, Seligson DB, LaRochelle J, et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18:894.</a></li><li><a class="nounderline abstract_t">Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115:2092.</a></li><li><a class="nounderline abstract_t">Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer 2009; 115:2290.</a></li><li><a class="nounderline abstract_t">Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746.</a></li><li><a class="nounderline abstract_t">Hakimi AA, Chen YB, Wren J, et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013; 63:848.</a></li><li><a class="nounderline abstract_t">Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.</a></li><li><a class="nounderline abstract_t">Leibovich BC, Lohse CM, Cheville JC, et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. Eur Urol 2018; 73:772.</a></li><li><a class="nounderline abstract_t">Correa AF, Jegede O, Haas NB, et al. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J Clin Oncol 2019; 37:2062.</a></li><li><a class="nounderline abstract_t">Peña-Llopis S, Vega-Rubín-de-Celis S, Liao A, et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012; 44:751.</a></li><li><a class="nounderline abstract_t">Kunkle DA, Egleston BL, Uzzo RG. Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review. J Urol 2008; 179:1227.</a></li><li><a class="nounderline abstract_t">Klatte T, Grubmüller B, Waldert M, et al. Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies. Eur Urol 2011; 60:435.</a></li><li><a class="nounderline abstract_t">Weight CJ, Kaouk JH, Hegarty NJ, et al. Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008; 179:1277.</a></li></ol></div><div id="topicVersionRevision">Topic 2969 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17326263" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17509291" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20970828" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25403213" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evaluation of the National Comprehensive Cancer Network and American Urological Association renal cell carcinoma surveillance guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21903243" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23916693" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566409" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Restaging clear cell renal carcinoma with 18F-FDG PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468753" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9507823" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146581" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146581" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Patterns of tumor recurrence and guidelines for followup after nephron sparing surgery for sporadic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28479239" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Renal Mass and Localized Renal Cancer: AUA Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776446" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A new protocol for the followup of renal cell carcinoma based on pathological stage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8911510" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of radionuclide bone scan and serum alkaline phosphatase in patients with metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441925" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10697316" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Radical surgery for the solitary bony metastasis from renal-cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11025692" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15310985" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Eastern Cooperative Oncology Group performance status predicts bone metastasis in patients presenting with renal cell carcinoma: implication for preoperative bone scans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26268680" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8946623" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9222697" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Hepatectomy for metastatic renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10893575" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31596672" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705072" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Surgical excision of isolated renal-bed recurrence after radical nephrectomy for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758610" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30561791" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for metachronous bilateral renal cell carcinoma: A surveillance, epidemiology, and end results analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9669818" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Stereotactic radiosurgery for brain metastasis from renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534903" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18671240" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31519468" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Brain Metastasis From Renal-Cell Carcinoma: An Institutional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076920" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Differences in organ system of distant metastasis by renal cell carcinoma subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19338559" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7974891" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Follow-up after partial or total nephrectomy for renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23665399" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19240241" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19296514" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19402057" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tissue biomarkers in renal cell carcinoma: issues and solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19124809" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036577" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454113" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29398265" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31216227" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22683710" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : BAP1 loss defines a new class of renal cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280512" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Excise, ablate or observe: the small renal mass dilemma--a meta-analysis and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21616582" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Laparoscopic cryoablation versus partial nephrectomy for the treatment of small renal masses: systematic review and cumulative analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18280507" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
